FDA Oncology
@FDAOncology
Followers
40K
Following
3K
Media
4K
Statuses
9K
FDA Oncology Center of Excellence expedites medical product development to improve the lives of people with cancer.
Silver Spring, MD
Joined February 2017
#FDA approves a treatment for relapsed or refractory multiple myeloma. https://t.co/KmL4fFaRPj
0
0
1
Join us today! FDA & @OSInstitute convening stakeholders Oct 10 to identify barriers, increase trial efficiency & advance innovative designs. New #osteosarcoma therapies needed NOW. Join a conversation that could change outcomes: https://t.co/6jGhAjWG5h
#RareDiseaseResearch
0
1
4
"Independent researcher raises concerns about scope of testing, chemical exposure following Smitty’s Supply explosion" - by @WAFB @georgiapecktv From the Article: "The @EPA has reported no imminent threat to human health following the explosion. However, Smith believes more
0
2
23
Breaking barriers in #osteosarcoma therapy development 💪! FDA/ @OSInstitute Oct 10 workshop brings together researchers, clinicians, pharma leaders, regulators & patient advocates. Register now: https://t.co/PLwPDgOvzK
0
1
5
#FDA approves an adjuvant treatment for cutaneous squamous cell carcinoma. https://t.co/iobgst33XP
0
5
13
🎯 Join the FDA's 10th Annual Clinical Outcome Assessment in Cancer Trials Workshop today, Oct 8, 1-3:30pm ET (virtual) to learn about progress in patient-reported outcomes. #CancerResearch #PatientVoice
https://t.co/KMEwBxW8Cm
1
0
4
Create apps with real depth. Our Three.js integration brings stunning 3D visuals and motion to your projects. If you want to build more immersive interactive experiences, this one's for you.
0
1
23
Recently, we welcomed hematology/oncology fellows to the FDA for an educational workshop on drug development and regulation, in collaboration with @ASCO. #OncEdFellows #OCEProjectSocrates #MedEd
2
0
7
Breaking barriers in #osteosarcoma therapy development 💪! FDA/ @OSInstitute Oct 10 workshop brings together researchers, clinicians, pharma leaders, regulators & patient advocates. Register now: https://t.co/PLwPDgOvzK
2
0
2
📊 How has patient-generated data transformed cancer drug approvals? Find out at FDA's 10th COA-CCT workshop Oct 8. Featuring 2024 PRO guidance review + real labeling examples. Virtual event. #FDA #ClinicalTrials #PatientReportedOutcomes
https://t.co/KMEwBxW8Cm
2
2
3
The FDA remains committed to advancing treatments for pediatric patients this #ChildhoodCancerMonth – and every month. Learn more about FDA's pediatric cancer initiatives: https://t.co/CJhUkUv68x
1
0
3
$NBIS has great revenue growth, but will probably end up a REIT...here's why Like $CRWV, Nebius's business model requires tremendous capex With large negative FCF, capex funds come from either debt or equity We think equity holders will get diluted or own a highly levered
6
3
13
Agenda and bios now posted!🚨 Oct 10, 2025: FDA & @OSInstitute workshop on advancing #osteosarcoma drug development. 🎯 Connecting research & regulatory pathways. https://t.co/PLwPDgOvzK
#CancerResearch
1
3
4
🧬Closing today! FDA's Project Collaborate seeks ideas from clinicians, researchers & patient advocates to analyze unique clinical trial data. Help shape the future of cancer regulatory science. https://t.co/bFqlC7vCr9
#OncologyResearch
3
0
1
FDA eliminates special safety requirements (REMS) for Caprelsa cancer drug after >decade of successful monitoring. Health care providers now have adequate knowledge to safely manage heart rhythm related risks without mandatory protocols. #CancerTreatment
https://t.co/iVEuPaVsfe
0
0
1
You’re not the customer, you’re the data stream. Every “free” message, file, and login you create is a micro-investment, just not in your own business. It’s funding someone else’s data vault.
1
0
2
🎯 Join the FDA's 10th Annual Clinical Outcome Assessment in Cancer Trials Workshop! Oct 8, 1-3:30pm ET (virtual). A decade of progress in patient-reported outcomes. Essential for researchers, clinicians & patient advocates. #CancerResearch #PatientVoice
https://t.co/KMEwBxW8Cm
4
6
4
🤝 Closing tomorrow! Cancer researchers, patients & advocates: share research ideas with FDA Oncology. Your question could become a pooled analysis study - with you as a collaborator on design, analysis & publication. Deadline: Sept 26 https://t.co/bFqlC7vCr9
1
3
3
The FDA remains committed to advancing treatments for pediatric patients this #ChildhoodCancerMonth – and every month. Learn more about FDA's pediatric cancer initiatives: https://t.co/CJhUkUv68x
1
0
3
📊 FDA's OCE has published game-changing pooled analyses of clinical trial data. Now YOU can propose the next research question through Project Collaborate. Selected ideas become collaborative studies with comprehensive datasets. https://t.co/bFqlC7vCr9
#RegulatoryScience
0
0
1
One breakdown can cost thousands. CarShield customers know they’re covered.
1
3
8
New #osteosarcoma therapies needed NOW. FDA & @OSInstitute convening stakeholders Oct 10 to identify barriers, increase trial efficiency & advance innovative designs. Join the conversation that could change outcomes! https://t.co/PLwPDgOvzK
#RareDiseaseResearch
0
0
2
🔬 Reflecting on a decade of progress! FDA Oncology Center of Excellence presents the 10th annual workshop on patient outcomes in cancer trials. Oct 8, virtual. Don't miss insights on future PRO data analysis. #OncologyResearch #RegulatoryScience
https://t.co/KMEwBxW8Cm
1
1
3
Since the 1950s, FDA has approved 60+ drugs with 85+ indications for pediatric cancers. With current scientific advances, the future looks promising. Learn more: https://t.co/uOs9DKdRnF
#ChildhoodCancerMonth
0
0
5